AIHTA - Publications - Search - Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL)

Rothschedl, E. and Wolf, S. (2022): Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Oncology Fact Sheet Nr. 89.

[thumbnail of Oncology Fact Sheet Nr.89.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
73kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
Language:English
Series Name:Oncology Fact Sheet Nr. 89
Deposited on:25 Apr 2022 14:43
Last Modified:16 May 2022 09:31

Repository Staff Only: item control page